
(b)(1) Not more than thirty days after an increase in wholesale acquisition cost of fifteen percent or greater over the preceding five calendar years or fifteen percent or greater in the preceding twelve months for a drug with a wholesale acquisition cost of one hundred dollars or more for a thirty-day supply, a pharmaceutical drug manufacturer shall submit a report to the [COMMISSIONER OF INSURANCE]. The report shall contain the following information:

(d) *Beginning [effective date of this law], 30 days or less after a manufacturer introduces a new prescription drug for sale in the United States at a price that exceeds the threshold established by the Centers for Medicare and Medicaid Services for specialty drugs in the Medicare Part D program, the manufacturer shall notify the department, in the form and manner prescribed by the department, of all the following information:

(a) A description of the marketing used in the introduction of the new prescription drug;
(b) The methodology used to establish the price of the new prescription drug;
(c) Whether the United States Food and Drug Administration granted the new prescription drug a breakthrough therapy designation or a priority review;
(d) If the new prescription drug was not developed by the manufacturer, the date of and the price paid for acquisition of the new prescription drug by the manufacturer;
(e) The manufacturer’s estimate of the average number of patients who will be prescribed the new prescription drug each month; and
(f) The research and development costs associated with the new prescription drug that were paid using public funds."

Section 5. Disclosure of pharmacy benefit management information.

(3) Within sixty days of receipt, the commissioner shall publish the report on the [INSURANCE DEPARTMENT’S] prescription drug price information website developed pursuant to subsection (a)(2) of section (4) of this Act. *For any pharmacy benefit manager with fewer than five (5) clients, the commissioner shall aggregate all the collected data and publish the aggregated data from all reports for that year required by this section in an appropriate location on the department’s internet website. The *combined aggregated* data from all of the reports must be published in a manner that does not disclose or tend to disclose proprietary or confidential information of any pharmacy benefit manager *or health plan [Carrier/Insurer]*.

(2) Within sixty days of receipt, the commissioner shall publish the report on the [INSURANCE DEPARTMENT’S] prescription drug price information website developed pursuant to subsection (a)(2) of section (41) of this Act. For any health [CARRIER/INSURER] with an affiliated pharmacy benefit manager with fewer than five (5) clients, the commissioner shall aggregate all the collected data and publish the aggregated data from all reports for that year required by this section in an appropriate location on the department’s internet website. The combined aggregated data from all of the reports must be published in a manner that does not disclose or tend to disclose proprietary or confidential information of any health [CARRIER/INSURER].